From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 1, Issue 5, 1999, Pages 154-162

  Bruce Lydiard, R ^a   Perera, Philip ^a   Batzar, Evan ^a   Clary, Cathryn M ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001703264     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v01n0504     Document Type: Article

References (34)

1. Fabre LF, Putnam HP III. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 1987;48:406-408
2. Lydiard RB, Stahl SM, Hertzman M, et al. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry 1997;58:484-491
3. Bielski RJ, Lydiard RB. Therapeutic trial participants: where do we find them and what does it cost? Psychopharmacol Bull 1997;33:75-78
4. Brauzer B, Goldstein BJ. Symptomatic volunteers: another patient dimension for clinical trials. J Clin Pharmacol 1973; 13:89-98
5. Bialik RJ, Ravindran AV, Bakish D, et al. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci 1995;20:265-270
6. Rapaport MH, Zisook S, Frevert T, et al. A comparison of demographic variables, symptoms profiles, and measurements of functioning in symptomatic volunteers in an outpatient population. J Clin Psychopharmacol 1996;16:242-246
7. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-18
8. Gorman JM. Comorbid depression and anxiety spectrum disorders Depress Anxiety 1996;4:160-168
9. Lydiard RB. Comorbidity of panic disorder, phobia, and major depression. Eur Psychiatry 1995;10(suppl 2):65S-66S
10. Hudson JI, Goldenberg DL, Pope HG Jr, et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;4:363-367
11. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990;51(12, suppl B):18-27
12. Nierenberg AA. The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 1994;55(9, suppl A):55-59
13. Smith WT, Londborg PD, Glaudin V, et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression. Am J Psychiatry 1998;155:1339-1345
14. Aguglia E, Casacchia M, Cassano GB. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 1993;8:197-202
15. Lydiard RB, Brawman-Mintzer O. Anxious depression. J Clin Psychiatry 1998;59(suppl 18): 10-17
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
17. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
19. Bech P, Gram LF, Dein E, et al. Quantitative rating of depressive states. Acta Psychiatr Scand 1975;51:161-170
20. Keller MB, Hanks DL. The natural history and heterogeneity of depressive disorders: implications for rational antidepressant therapy. J Clin Psychiatry 1994;55(9, suppl A):25-31
21. Keller MB, Hirschfeld RM, Hanks D. Double depression: a distinctive subtype of unipolar depression. J Affect Disord 1997;45:65-73
22. Sanderson WC, Beck AT, Beck J. Syndrome comorbidity in patients with major depression or dysthymia: prevalence and temporal relationships. Am J Psychiatry 1990;147:1025-1028
23. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371
24. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder a double-blind multicenter trial. Am J Psychiatry 1998;155:1189-1195
25. Greist-J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three-dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder Arch Gen Psychiatry 1995;52:289-295
26. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998;55:1010-1016
27. Cornwall PL, Scott J. Partial remission in depressive disorders. Acta Psychiatr Scand 1997;95:265-271
28. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619
29. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology 1998;31:5-14
30. Van Londen L, Molenaar RP, Goekoop JG, et al. Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 1998;28:731-735
31. Hirschfeld RM. Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 1996;11:211-217
32. Reynolds CF. Treatment of major depression in later life: a life cycle perspective. Psychiatr Q 1997;68:221-246
33. Thase ME, Blomgren SL, Birkett MA, et al. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58:16-21
34. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56:30-34